High prevalence of gene abnormalities in young patients with lung cancer

Journal of Thoracic Disease

Volumn 5, Issue 1, 2013, Pages 27-30

  Nagashima, Osamu ^a   Ohashi, Rina ^b   Yoshioka, Yasuko ^a   Inagaki, Ai ^b   Tajima, Manabu ^b   Koinuma, Yoshika ^b   Iwakami, Shin Ichiro ^c   Iwase, Akihiko ^d   Sasaki, Shinichi ^a   Tominaga, Shigeru ^a   Takahashi, Kazuhisa ^b  

^a JUNTENDO UNIVERSITY URAYASU HOSPITAL   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c JUNTENDO UNIVERSITY SHIZUOKA HOSPITAL   (Japan)

^d JUNTENDO TOKYO KOTO GERIATRIC MEDICAL CENTER   (Japan)

Author keywords

Driver oncogene; EGFR; EML4 ALK; Lung cancer; Young patients

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GEMCITABINE; HYBRID PROTEIN; MICROTUBULE ASSOCIATED PROTEIN 4; PACLITAXEL; PEMETREXED;

ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; EGFR GENE; EML4 ALK FUSION GENE; FEMALE; GENE ABNORMALITY; GENE DELETION; GENE FUSION; GENE MUTATION; GENETIC DISORDER; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALE; ONCOGENE; ONCOGENE K RAS; RETROSPECTIVE STUDY; SMOKING; SURVIVAL TIME;

EID: 84876743233     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2012.12.02     Document Type: Article

References (13)

1. Jubelirer SJ, Wilson RA. Lung cancer in patients younger than 40 years of age. Cancer 1991;67:1436-8.
2. Larrieu AJ, Jamieson WR, Nelems JM, et al. Carcinoma of the lung in patients under 40 years of age. Am J Surg 1985;149:602-5.
3. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
4. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
5. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6.
6. Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009;15:3143-9.
7. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007;98:1817-24.
8. Toyooka S, Takano T, Kosaka T, et al. Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma. Cancer Sci 2008;99:303-8.
9. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008;3:13-7.
10. Takahashi T, Sonobe M, Kobayashi M, et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 2010;17:889-97.
11. Martelli MP, Sozzi G, Hernandez L, et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 2009;174:661-70.
12. Paik JH, Choe G, Kim H, et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol 2011;6:466-72.
13. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 2009;22:508-15.